Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 InNexus Biotech, Affirmed Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

InNexus Biotech, Affirmed Therapeutics

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InNexus Biotechnology and Affimed Therapeutics have formed a collaboration utilizing Affimed’s antibodies and InNexus’ SuperAntibody antibody enhancement drug development platform. The companies will complete feasibility studies and InNexus will have a right to license one of Affimed’s antibodies, while Affimed will have the right to license SuperAntibody Technology for one antibody. Exercise-of-rights is expected to trigger payments in the form of licensing fees, milestone payments and sales royalty.

“This is a unique product development opportunity for both companies, leveraging Affimed’s antibody generating capability with the potency-enhancing SuperAntibody Technology of InNexus,” said Dr. Charles Morgan, president and chief scientific officer of InNexus. “This provides us with the first candidate, targeting colon cancer, to enter our SuperAntibody Bioequivalent Program.” InNexus’ SuperAntibody Bioequivalent Program, as recently announced, will produce SuperAntibody versions of existing FDA-cleared antibodies.

Dr. Melvyn Little, chief scientific officer of Affimed said, “We are very impressed with the SuperAntibody technology of InNexus and this agreement will allow us to develop superior products based on full length antibodies with high market values. Affimed’s own antibody formats, in particular our proprietary TandAb technology using tetravalent bispecific antibodies to recruit immune effector cells for lysing tumor cells are complimented by this collaboration.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics